MP, MPT, or intermediate-dose melphalan for multiple myeloma.32
| Response Quality . | MP (n= 196) . | MPT (n= 125) . | Mel 100 (n= 126) . |
|---|---|---|---|
| Abbreviations: Mel 100, patients received two cycles of infusional vincristine, doxorubicin, and oral dexamethasone, followed by stem cell mobilization and up to two autologous stem cell transplants with melphalan as a preparative regimen at 100 mg/m2; mos., months; MP, melphalan and prednisone; MPT, melphalan and prednisone with thalidomide; n, number of patients in each cohort | |||
| Complete response | 2% | 16% | 17% |
| At least a very good partial response | 8% | 50% | 43% |
| At least a partial response | 40% | 81% | 73% |
| Response durability | |||
| Progression-free survival | 17.1 mos. | 27.6 mos. | 19.4 mos. |
| Overall survival | 32.2 mos. | 53.6 mos. | 38.6 mos. |
| Response Quality . | MP (n= 196) . | MPT (n= 125) . | Mel 100 (n= 126) . |
|---|---|---|---|
| Abbreviations: Mel 100, patients received two cycles of infusional vincristine, doxorubicin, and oral dexamethasone, followed by stem cell mobilization and up to two autologous stem cell transplants with melphalan as a preparative regimen at 100 mg/m2; mos., months; MP, melphalan and prednisone; MPT, melphalan and prednisone with thalidomide; n, number of patients in each cohort | |||
| Complete response | 2% | 16% | 17% |
| At least a very good partial response | 8% | 50% | 43% |
| At least a partial response | 40% | 81% | 73% |
| Response durability | |||
| Progression-free survival | 17.1 mos. | 27.6 mos. | 19.4 mos. |
| Overall survival | 32.2 mos. | 53.6 mos. | 38.6 mos. |